BlackRock Future Health ETF (BMED) Holdings
BMED holdings summary
as of Oct 24, 2026- Holdings
- 54 positions listed
- Top 10 weight
- 42.5% of net assets
- Effective holdings
- 32 equal-weight equivalent
- Largest holding
- GILD 5.58% Gilead Sciences, Inc.
- Annual turnover
- 73.6% of the portfolio traded
All BMED holdings
| # | Name | ||||||
|---|---|---|---|---|---|---|---|
| 1 | GILD | Gilead Sciences, Inc. | Healthcare | 5.58% | $788,748.61 | $193.67B | — |
| 2 | MRNA | Moderna, Inc. | Healthcare | 5.08% | $717,457.93 | $87.04B | — |
| 3 | DHR | Danaher Corporation | Healthcare | 5.05% | $713,599.41 | $161.01B | 40.8 |
| 4 | ABBV | AbbVie Inc. | Healthcare | 4.83% | $682,646.47 | $504.37B | 80.6 |
| 5 | TMO | Thermo Fisher Scientific Inc. | Healthcare | 4.17% | $589,943.14 | $255.13B | 37.1 |
| 6 | IQV | IQVIA Holdings Inc. | Healthcare | 3.85% | $544,474.84 | $43.93B | 33.2 |
| 7 | BIIB | Biogen Inc. | Healthcare | 3.73% | $527,683.93 | $34.37B | 41.3 |
| 8 | MTD | Mettler-Toledo International Inc. | Healthcare | 3.68% | $519,981.03 | $32.51B | 36.6 |
| 9 | VRTX | Vertex Pharmaceuticals Incorporated | Healthcare | 3.33% | $471,318.49 | $126.66B | 28.9 |
| 10 | MRK | Merck & Co., Inc. | Healthcare | 3.18% | $449,227.43 | $360.08B | 115.8 |
| 11 | ROP | Roche Holding AG | Healthcare | 2.91% | $411,688.16 | — | — |
| 12 | EW | Edwards Lifesciences Corporation | Healthcare | 2.87% | $404,946.36 | $49.92B | 51.5 |
| 13 | A | Agilent Technologies, Inc. | Healthcare | 2.53% | $357,541.73 | $48.77B | 34.1 |
| 14 | AMGN | Amgen Inc. | Healthcare | 2.50% | $353,881.08 | $233.82B | 26.9 |
| 15 | WAT | Waters Corporation | Healthcare | 2.38% | $336,652.03 | $42.90B | 110.6 |
| 16 | HALO | Halozyme Therapeutics, Inc. | Healthcare | 2.33% | $329,189.40 | $13.83B | 35.6 |
| 17 | GMAB | Genmab A/S | Healthcare | 2.21% | $312,525.70 | $22.75B | 29.1 |
| 18 | DXCM | DexCom, Inc. | Healthcare | 2.14% | $302,872.34 | $32.47B | 34.1 |
| 19 | ILMN | Illumina, Inc. | Healthcare | 1.91% | $269,601.47 | $39.64B | 49.0 |
| 20 | CRL | Charles River Laboratories International, Inc. | Healthcare | 1.73% | $243,962.83 | $14.46B | — |
| 21 | ARGX | argenx SE | Healthcare | 1.65% | $233,023.30 | $51.51B | 31.2 |
| 22 | PFE | Pfizer Inc. | Healthcare | 1.54% | $217,504.43 | $168.60B | 38.9 |
| 23 | GALD | Galderma Group N | Healthcare | 1.51% | $212,910.96 | — | — |
| 24 | GH | Guardant Health, Inc. | Healthcare | 1.44% | $202,989.06 | $21.28B | — |
| 25 | ROIV | Roivant Sciences Ltd. | Healthcare | 1.37% | $193,830.38 | $24.22B | — |
| 26 | NBIX | Neurocrine Biosciences, Inc. | Healthcare | 1.37% | $193,575.98 | $13.79B | 19.9 |
| 27 | TEVA | Teva Pharmaceutical Industries Ltd | Healthcare | 1.34% | $189,986.00 | — | — |
| 28 | BMY | Bristol-Myers Squibb Company | Healthcare | 1.32% | $186,579.77 | $122.05B | 13.2 |
| 29 | ABT | Abbott Laboratories | Healthcare | 1.26% | $177,901.64 | $181.50B | 33.8 |
| 30 | JNJ | Johnson & Johnson | Healthcare | 1.25% | $176,247.99 | $615.87B | 38.8 |
| 31 | CYTK | Cytokinetics, Incorporated | Healthcare | 1.24% | $175,399.96 | $8.61B | — |
| 32 | NOVN | Novartis AG | Healthcare | 1.24% | $175,117.29 | — | — |
| 33 | 0O14 | MERCK Kommanditgesellschaft auf Aktien | Healthcare | 1.22% | $172,912.42 | — | — |
| 34 | 2269 | WuXi Biologics | Healthcare | 1.19% | $168,615.76 | — | — |
| 35 | BMRN | BioMarin Pharmaceutical Inc. | Healthcare | 1.02% | $144,136.08 | $10.58B | 147.8 |
| 36 | COR | Cencora | Healthcare | 1.01% | $142,157.36 | $65.06B | 25.3 |
| 37 | PTGX | Protagonist Therapeutics, Inc. | Healthcare | 0.88% | $124,998.97 | $8.33B | 125.0 |
| 38 | TEM | Tempus AI, Inc. | Healthcare | 0.85% | $120,221.76 | $11.68B | — |
| 39 | UCB | UCB SA | Healthcare | 0.83% | $117,621.15 | — | — |
| 40 | AXSM | Axsome Therapeutics, Inc. | Healthcare | 0.72% | $101,169.45 | $8.23B | — |
| 41 | BRKR | Bruker Corporation | Healthcare | 0.67% | $94,738.59 | $8.35B | — |
| 42 | ALKS | Alkermes plc | Healthcare | 0.57% | $80,675.50 | $6.92B | 108.5 |
| 43 | RVMD | Revolution Medicines, Inc. | Healthcare | 0.53% | $75,177.47 | $38.14B | — |
| 44 | PTCT | PTC Therapeutics, Inc. | Healthcare | 0.45% | $63,587.79 | $4.94B | — |
| 45 | COGT | Cogent Biosciences, Inc. | Healthcare | 0.41% | $57,368.93 | $5.12B | — |
| 46 | DNTH | Dianthus Therapeutics, Inc. | Healthcare | 0.40% | $56,111.03 | $4.03B | — |
| 47 | MBX | MBX Biosciences, Inc. | Healthcare | 0.38% | $54,231.24 | $2.39B | — |
| 48 | VRDN | Viridian Therapeutics, Inc. | Healthcare | 0.31% | $43,588.52 | $2.16B | — |
| 49 | SGMT | Sagimet Biosciences Inc. | Healthcare | 0.13% | $18,769.63 | $568.7M | — |
| 50 | SMMT | Summit Therapeutics Inc. | Healthcare | 0.08% | $11,349.41 | $11.67B | — |
| 51 | EIKN | Eikon Therapeutics, Inc. | Healthcare | 0.07% | $10,557.92 | $401.9M | — |
| 52 | AVTX | Avalo Therapeutics, Inc. | Healthcare | 0.04% | $6,006.85 | $604.4M | — |
| 53 | MRTX | Mirati Ther | Healthcare | 0.00% | $240.27 | — | — |
| 54 | BPMC | Blueprint Medicines Corp | Healthcare | 0.00% | $98.94 | — | — |
Weights as a percentage of net assets. Value held = weight × net assets ($14.1M). Market cap and P/E from each company's latest fundamentals (U.S.-listed stocks).
BMED sector breakdown
Sum of the weights of the holdings in each sector.
BMED top industries
BMED overlap with other ETFs
| ETF | Fund | Overlap | Shared holdings | Expense ratio |
|---|---|---|---|---|
| DIA | SPDR Dow Jones Industrial Average ETF | 5.5% | 3 of 30 | 0.16% |
| SPY | SPDR S&P 500 ETF | 5.1% | 23 of 502 | 0.09% |
| VTI | Vanguard Total Stock Market ETF | 4.8% | 45 of 2,941 | 0.03% |
| QQQ | Invesco QQQ ETF | 3.2% | 6 of 101 | 0.17% |
| VXUS | Vanguard Total International Stock ETF | 1.8% | 10 of 8,035 | 0.05% |
| IWM | iShares Russell 2000 ETF | 1.6% | 12 of 1,962 | 0.19% |
Overlap = sum over shared holdings of the smaller of the two weights. 100% means identical portfolios.
About the BMED portfolio
BlackRock Future Health ETF holds 54 positions. The ten largest make up 42.5% of the fund and the top 50 94.2%, so it behaves like a portfolio of about 32 equally weighted stocks. The biggest positions are Gilead Sciences, Inc. (5.58%), Moderna, Inc. (5.08%), Danaher Corporation (5.05%), AbbVie Inc. (4.83%), Thermo Fisher Scientific Inc. (4.17%).
By sector, Healthcare is 94.3%. Holdings data is from the fund's latest portfolio as reported by EODHD on October 24, 2026; positions change as the fund rebalances.
Related: BMED chart, BMED performance, BMED dividends, BMED valuation, BMED overview.
BMED holdings FAQ
How many holdings does BMED have?
BMED holds 54 positions as of October 24, 2026.
What are the top 10 holdings of BMED?
The ten largest holdings are Gilead Sciences, Inc. (5.58%), Moderna, Inc. (5.08%), Danaher Corporation (5.05%), AbbVie Inc. (4.83%), Thermo Fisher Scientific Inc. (4.17%), IQVIA Holdings Inc. (3.85%), Biogen Inc. (3.73%), Mettler-Toledo International Inc. (3.68%), Vertex Pharmaceuticals Incorporated (3.33%), Merck & Co., Inc. (3.18%). Together they are 42.5% of the fund.
What percentage of BMED is Gilead Sciences, Inc.?
Gilead Sciences, Inc. is the largest holding at 5.58% of net assets, about $788,748.61 of the fund's $14.1M.
How concentrated is BMED?
The top 10 holdings are 42.5% of the fund. By the effective number of holdings (1 divided by the sum of squared weights) BMED behaves like a portfolio of about 32 equally weighted stocks.